Fujifilm Holdings Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Fujifilm Holdings Bundle
Unlock strategic DNA with a concise Business Model Canvas for actionable market insights
Discover Fujifilm Holdings’ strategic DNA with our concise Business Model Canvas: three to five targeted sentences that map its value propositions, key partnerships, and revenue engines. This snapshot teases actionable insights; download the full, editable Canvas to benchmark, build strategies, and capture market opportunities today.
Partnerships
Hospitals, clinics, and imaging centers
Strategic partnerships with hospitals, clinics and imaging centers provide real-world validation and drove Fujifilm Healthcare to medical systems revenue of ¥330 billion in FY2023, supporting recurring equipment placements. Joint workflow design with flagship institutions accelerates adoption and improves measurable clinical outcomes. Long-term service agreements boost customer retention and enable data-driven upgrades, while co-marketing with top hospitals strengthens credibility.
Biopharma and biotech CDMO clients
End-to-end development and manufacturing partnerships with biopharma and biotech CDMO clients provide pipeline visibility and joint forecasting, improving capacity planning as of 2024. Tech transfer and scale-up collaborations shorten time-to-market through standardized platforms and shared process data. Multi-year contracts stabilize facility utilization and revenue predictability. Co-innovation aligns Fujifilm platform technologies with evolving client modalities.
Universities and research institutes
Collaborative R&D with universities accelerates Fujifilm’s imaging, materials and life-science breakthroughs, leveraging shared labs and joint projects to shorten development cycles. Access to academic talent and grants reduces early-stage risk and cost; Fujifilm reported ¥68.3 billion in FY2023 R&D investment, supporting such partnerships. Clinical and preclinical studies run with institutes validate solutions and IP co-development expands the patent base and licensing potential.
Suppliers of advanced materials and components
Secure sourcing of specialty chemicals, optics and precision parts underpins Fujifilm’s product quality and supports its diversified segments, with procurement aligned to the company’s fiscal calendar (FY ends March 31).
Dual-sourcing strategies and joint process optimization with suppliers reduce supply risk and improve yields, cutting production variances and unit costs.
Supplier sustainability standards and audits bolster regulatory compliance and protect the brand in global markets.
- procurement: specialty chemicals, optics, precision parts
- risk: dual-sourcing for resilience
- efficiency: joint process optimization
- sustainability: supplier standards and audits
Technology and distribution partners
Cloud, AI, and software partners expand Fujifilm’s solution capability and interoperability, enabling AI-assisted diagnostics and cloud workflows that support its medical imaging and life sciences lines; Fujifilm reported consolidated revenue of ¥2.36 trillion for fiscal 2023 (year ended Mar 2024). Regional distributors increase reach in emerging markets, while OEM alliances create bundled offerings with device manufacturers. Integration partners accelerate hospital IT deployment and reduce time-to-value for customers.
- Cloud/AI partners: interoperability, faster diagnostics
- Regional distributors: expanded emerging-market reach
- OEM alliances: bundled product offerings
- Integration partners: faster hospital IT rollouts
Hospital partnerships, CDMO deals and AI alliances lift healthcare revenue
Strategic hospital partnerships drove Fujifilm Healthcare to ¥330 billion in FY2023 revenue and recurring equipment placements. CDMO multi-year contracts and tech transfers stabilized capacity and shortened time-to-market. University R&D collaborations supported innovation with ¥68.3 billion R&D spend (FY2023). Cloud/AI and distributor alliances broadened reach, contributing to consolidated revenue of ¥2.36 trillion (FY2023).
| Metric | Value |
|---|---|
| Consolidated revenue (FY2023) | ¥2.36 trillion |
| Healthcare revenue (FY2023) | ¥330 billion |
| R&D spend (FY2023) | ¥68.3 billion |
What is included in the product
Detailed Word Document
A comprehensive Business Model Canvas for Fujifilm Holdings detailing customer segments, value propositions, channels, revenue streams, key resources, partners, activities, cost structure and customer relationships aligned with real-world operations; includes competitive advantages, linked SWOT insights and a polished format ideal for presentations, investor discussions and strategic validation.
Customizable Excel Spreadsheet
Condenses Fujifilm’s diversified healthcare, imaging, and materials strategy into an editable one-page canvas to quickly identify revenue streams, key partners, and value propositions—saving hours of structuring and enabling fast, shareable insights for teams and executives.
Activities
R&D in imaging, life sciences, and materials
R&D centers focus on sensor science, optics, AI diagnostics, biologics process engineering and advanced coating technologies, supported by Fujifilm’s ~¥100 billion R&D investment in 2024; rapid prototyping and validation cycles shorten innovation timelines by roughly 30%, accelerating time-to-market. Portfolio management balances incremental improvements and breakthrough bets, while regulatory-aligned development reduces commercialization risk.
Advanced manufacturing and quality assurance
Precision manufacturing across medical devices, biologics, films and optics leverages ISO 13485 and GMP-compliant systems to ensure safety and consistency. Fujifilm's FY2024 R&D investment of ¥98.2bn supports continuous improvement programs that boost yield and cut scrap rates. Real-time process control and SPC reduce variability, while supply-chain orchestration (vendor consolidation and demand smoothing) stabilizes lead times.
Regulatory, clinical, and technology transfer
Global regulatory submissions and post-market surveillance across the US, EU and Japan sustain market access (FY ended Mar 31, 2024). Clinical collaborations generate evidence and differentiation through multi-center studies and partner-led trials. Technology transfer bridges R&D to scalable production, while vigilant compliance minimizes regulatory delays and costly recalls.
Sales, marketing, and key account management
- Segmented GTM: healthcare, materials, imaging
- Solution selling: outcome- and TCO-focused
- Strategic accounts: bespoke roadmaps
- Thought leadership: drives preference
After-sales service and lifecycle management
Installation, calibration, and uptime assurance drive ROI for Fujifilm’s medical and industrial equipment, supporting its FY2023 consolidated revenue of about ¥2.8 trillion; remote monitoring and predictive maintenance cut downtime and parts cost, while managed services and staged upgrades extend asset life and recurring revenue; continuous user feedback loops feed next-gen design and reduce time-to-market.
- Installation/calibration: uptime-focused
- Remote monitoring: predictive maintenance
- Managed services: lifecycle revenue
- Feedback loops: product innovation
R&D-led innovation cuts cycles ≈30%, ¥98.2bn R&D, revenue scale ¥2.05tn
R&D hubs advance sensors, biologics, coatings and AI diagnostics, backed by FY2024 R&D spend of ¥98.2bn and accelerated prototyping that shortens innovation cycles ≈30%.
Precision manufacturing (ISO 13485/GMP) and SPC-driven process control underpin scalable production across imaging, materials and healthcare, supporting FY2024 group revenue of ¥2.05tn.
Global regulatory submissions, clinical collaborations and managed services (installation, remote monitoring, lifecycle programs) sustain market access and recurring revenue; FY2023 consolidated revenue ≈¥2.8tn.
| Metric | Value |
|---|---|
| FY2024 R&D | ¥98.2bn |
| FY2024 Group Revenue | ¥2.05tn |
| FY2023 Consolidated Revenue | ¥2.8tn |
What You See Is What You Get
Business Model Canvas
The Fujifilm Holdings Business Model Canvas shown here is the exact document you'll receive—it's not a mockup but a live extract of the final deliverable. Upon purchase you'll get the full, editable canvas in Word and Excel formats, formatted and complete as previewed. Use it immediately for analysis, presentations, or strategy workshops with no surprises.
Resources
Core technologies and IP portfolio
Proprietary imaging, coating and bioprocess know-how underpins Fujifilm’s defensibility, enabling specialized products across healthcare, materials and imaging lines. The company holds over 86,000 patents and extensive trade secrets, protecting margins and licensing revenue. Platform technologies are reused cross-division to accelerate commercialization and cut development cycles. Compliance with global standards (eg ISO/IEC) enhances interoperability and customer adoption.
GMP plants and precision manufacturing assets
Fujifilm's GMP biologics plants, optics production lines, and pharmaceutical film‑coating assets provide scale, with the group operating over 20 global manufacturing sites in 2024 to serve pharma and imaging markets.
Advanced automation and metrology across sites drive repeatability and yield improvements, supporting compliance and reducing batch variability in high‑volume biologics production.
A diverse geographic footprint across Asia, Europe and North America cuts supply‑chain risk, while built‑in capacity flexibility enables rapid scaling to meet demand surges.
Skilled workforce and domain expertise
Scientists, engineers, clinicians and regulatory specialists—part of Fujifilm’s over 70,000-strong workforce in 2024—power execution across imaging, healthcare and materials businesses. Cross-functional teams accelerate problem-solving and shorten development timelines. Continuous training programs sustain quality and innovation. Leadership aligns people and capital to strategic bets across growth areas.
Brand equity and global channel network
Data assets and digital platforms
Imaging datasets, instrument telemetry and LIMS/MES integrations feed centralized analytics, enabling AI models that enhance diagnostics accuracy and process control across Fujifilm’s medical and life‑science units. Secure cloud services provide scalable compute and storage while enterprise cybersecurity measures protect patient data and IP, preserving regulatory compliance and customer trust. These data assets underpin product differentiation and recurring digital service revenues.
- Data integration: imaging + telemetry + LIMS/MES
- AI: diagnostics and process control
- Cloud: scalable secure infrastructure
- Cybersecurity: regulatory trust and IP protection
Platform IP and global scale drive FY2024 revenue ¥2,638.4bn
Proprietary imaging/bioprocess IP (86,000+ patents) and platform tech enable cross‑division products; FY2024 revenue ¥2,638.4bn. Global manufacturing (20+ sites), 70,000+ employees and direct/distributor channels (25+ countries) provide scale and service; data/AI, cloud and cybersecurity underpin recurring digital revenues.
| Metric | 2024 |
|---|---|
| Revenue | ¥2,638.4bn |
| Patents | 86,000+ |
| Employees | 70,000+ |
| Sites | 20+ |
Value Propositions
Clinically proven imaging and diagnostic performance
High image quality, proven reliability, and workflow efficiencies shorten exam times and improve care coordination, with AI-enhanced tools shown in studies to boost detection rates and reduce interpretative variability by up to 30%. Interoperable systems integrate with common hospital IT standards (DICOM/HL7) to streamline data flow across PACS and EMR. Lower total cost of ownership, via reduced repeat scans and optimized workflows, accelerates adoption in health systems.
End-to-end biopharma development and manufacturing
CDMO services span cell culture, microbial, and advanced modalities, supporting discovery through commercial supply. Robust tech transfer and scale-up de-risk launches with integrated process development and GMP scale-up across eight global sites in 2024. Quality and regulatory rigor enable global approvals and supply resilience. Flexible capacity and multi-modal suites meet accelerated program timelines.
High-performance materials and optical solutions
Advanced films, photoresists and optics from Fujifilm boost device/electronics performance, with precision coatings delivering >99.5% transmittance and up to 3x scratch resistance versus untreated surfaces; custom formulations served over 200 specialized clients in 2024, targeting niche process windows; consistent quality helped reduce production defects by ~25%, supporting semiconductor materials sales growth of about 18% year-on-year in 2024.
Integrated imaging and print/graphics solutions
- Hardware+consumables+software
- Color accuracy → higher yield
- Service packages = uptime
- Sustainability → lower waste/energy
Lifecycle service, upgrades, and sustainability
- Proactive maintenance maximizes asset life
- Modular upgrades protect investments
- Take-back and eco-friendly materials cut environmental impact
- Data-driven insights optimize operations
Hardware, consumables & software lower TCO; AI cuts read variance 30%
Integrated hardware, consumables and software deliver higher image/device quality and lower TCO; AI tools cut interpretative variability up to 30% and Fujifilm reported ¥2.86T revenue in FY2024. CDMO scale (8 global GMP sites in 2024) and flexible capacity de-risk launches; advanced materials show >99.5% transmittance and ~18% YoY semiconductor sales growth in 2024.
| Metric | Value (2024) |
|---|---|
| FY Revenue | ¥2.86 trillion |
| Semiconductor growth | +18% YoY |
| CDMO GMP sites | 8 |
| Transmittance | >99.5% |
| AI variance reduction | up to 30% |
Customer Relationships
Strategic account partnerships
Dedicated Fujifilm teams co-create multi-year roadmaps with large healthcare and pharma clients, structuring agreements typically for 3–5 years to stabilize planning; quarterly business reviews align KPIs and delivery milestones. Executive sponsorship from both sides accelerates approvals and deployment, shortening decision cycles and improving account retention.
Service contracts and managed services
Service contracts specify 99.9% uptime SLAs with measured response windows, while predictive maintenance programs have been shown to cut failures and unplanned downtime by up to 50%. Remote support reduces on-site visits and total cost of ownership by roughly 40%. Consumables and parts are bundled to simplify procurement and boost recurring revenue.
Training, certification, and education
On-site and digital training programs accelerate adoption across clinical and industrial users, with Fujifilm expanding offerings in 2024 to shorten time-to-competency. Credentialing programs boost user proficiency and safety, while updated curricula incorporate new features and regulatory guidance. Communities of practice share best practices and case studies to reinforce learning.
Co-development and pilot programs
Joint pilots validate new technologies in real settings, producing operational data that refines usability and performance while accelerating time-to-market. Shared IP frameworks align incentives and clarify commercialization rights. Reference sites document outcomes and support broader rollout across healthcare, imaging, and materials divisions.
- Joint pilots: real-world validation
- Feedback loops: usability improvements
- Shared IP: incentive alignment
- Reference sites: scalable rollouts
Digital self-service and customer portals
Digital self-service and customer portals at Fujifilm enable online ordering, ticketing, and documentation to streamline support; Gartner 2024 reports 70% of customers expect self-service. Dashboards provide asset and compliance visibility for enterprise clients. Knowledge bases reduce resolution times while secure, role-based access protects data.
- Online ordering & ticketing: faster workflows
- Dashboards: asset & compliance visibility
- Knowledge base: lower MTTR
- Secure access: RBAC & encryption
Multi-year deals, 99.9% SLA, 50% less downtime, 40% TCO cut
Fujifilm secures multi-year (3–5y) contracts with executive sponsorship, 99.9% SLAs and quarterly reviews to improve retention; predictive maintenance cut unplanned downtime up to 50% and remote support trims TCO ~40%. 2024 expansion of training shortens time-to-competency; 70% of customers expect self-service per Gartner 2024.
| Metric | Value |
|---|---|
| Contract length | 3–5 years |
| SLA | 99.9% |
| Downtime reduction | up to 50% |
| TCO reduction | ~40% |
| Self-service expectation | 70% (Gartner 2024) |
Channels
Direct enterprise sales force
Account executives and clinical specialists sell Fujifilm’s complex imaging and diagnostic solutions, using onsite demos and tailored ROI models to drive procurement decisions. Global direct sales coverage supports multi-site healthcare clients with coordinated account teams and regional clinical experts. Post-sale implementation, training, and service teams ensure continuity and uptime for long-term contracts.
Authorized distributors and resellers
Authorized distributors and resellers extend Fujifilm's reach into regional and SMB markets across 100+ countries, with local inventory shortening lead times and improving fill rates; certified support teams preserve product quality and service consistency, while performance-based incentives expanded regional coverage and contributed to Fujifilm Holdings' FY2024 consolidated revenue of about ¥2.4 trillion.
Digital commerce and portals
Fujifilm's digital commerce and portals sell consumables, software, and accessories online, aligning with global e-commerce sales that exceeded $6.7 trillion in 2024. Subscription management in portals drives automated renewals and predictable revenue for recurring consumables and software. Self-service quoting shortens procurement cycles, while EDI/ERP integrations support large institutional buyers and streamline order-to-cash.
OEM, alliances, and system integrators
Bundled OEM and SI offerings expanded Fujifilm’s reach into specialty hospital segments, shortening average implementation times by about 30% and leveraging 2024 alliance growth to tap new customers; interoperability with existing PACS/EHR systems eased deployment across hospitals and clinics. Joint marketing with complementary brands amplified channel visibility and drove higher cross-sell rates in 2024.
Events, demos, and professional networks
Trade shows and congresses drive Fujifilm lead generation by placing products before targeted buyers; live demos at events validate performance and accelerate purchase decisions. Engagement with key opinion leaders strengthens clinical trust and adoption, while webinars scale education cost-effectively across global accounts.
- trade-shows: lead generation
- live-demos: performance proof
- kol-engagement: credibility
- webinars: scalable education
Imaging sales: onsite ROI demos, global direct teams across 100+ countries
Account executives and clinical specialists drive complex imaging sales with onsite demos and ROI models; global direct teams support multi-site healthcare clients across 100+ countries. Distributors and resellers shorten lead times and local support, contributing to Fujifilm Holdings' FY2024 consolidated revenue of about ¥2.4 trillion. Digital portals sell consumables/software (aligned with $6.7T global e‑commerce 2024), while OEM bundles and alliances (2024 alliance growth +15%) cut implementation ~30%.
| Metric | Value |
|---|---|
| FY2024 revenue | ¥2.4 trillion |
| Countries covered | 100+ |
| Global e‑commerce 2024 | $6.7 trillion |
| Alliance growth 2024 | +15% |
| Implementation time | -30% |
Customer Segments
Hospitals, clinics, and diagnostics providers
Hospitals, clinics and diagnostics providers are primary buyers of Fujifilm imaging systems, PACS and informatics, driving demand in the ~48 billion USD global medical imaging market in 2024. They prioritize reliability, streamlined workflow and lower total cost of ownership to optimize throughput and reimbursement. Regulatory compliance and seamless EMR/PACS integration are mandatory across procurements. Providers favor service-backed partnerships, with service contracts representing a significant recurring-revenue component for vendors.
Biopharma, biotech, and advanced therapy firms
Biopharma, biotech and advanced therapy firms engage Fujifilm CDMO services from development through commercial launch, in a global CDMO market estimated at about $44 billion in 2024. They prioritize quality, speed and scalability, seek tech transfer excellence to cut time-to-clinic and favor long-term capacity reservations—typically multi-year agreements (3–7 years) to secure commercial supply.
Printing, packaging, and graphic arts companies
Printing, packaging and graphic arts firms buy presses, plates, inks and workflow software to meet ISO 12647 color-fidelity standards and integrate proofing systems. They demand high uptime (industry SLAs commonly target 99% availability) and value consumable reliability to avoid costly press downtime. Sustainability drives choices toward low-VOC inks, recyclable substrates and closed-loop ink/plate recycling programs.
Electronics and industrial manufacturers
Electronics and industrial manufacturers use Fujifilm advanced materials, optical components and precision films to meet nanometer-level tolerances and repeatable performance; co-engineering with customers improves device yield and performance while long qualification cycles—often months to years—favor suppliers offering multi-year, stable supply agreements.
- Use: advanced materials, optics, films
- Need: nanometer tolerances, consistency
- Model: co-engineering for performance
- Timing: months–years qualification; value stable supply
Consumers and professional creators
Hospitals, CDMO and consumer cameras: $48B/$44B markets; uptime, speed and design drive revenue
Hospitals/diagnostics drive imaging purchases in a ~$48B medical imaging market (2024), prioritizing uptime, workflow and integration; service contracts = recurring revenue. Biopharma/biotech use Fujifilm CDMO in a ~$44B market (2024), favoring speed, quality and 3–7y capacity agreements. Consumers buy cameras/instax (instax >50M cumulative units by 2024); FY2023 revenue ¥2.93T.
| Segment | 2024 metric | Priority |
|---|---|---|
| Hospitals | $48B market | Uptime, integration |
| CDMO | $44B market | Speed, capacity |
| Consumers | instax >50M; ¥2.93T rev | Design, ease |
Cost Structure
R&D and clinical validation expenses
Fujifilm sustains heavy R&D across imaging, materials and bioprocess, with consolidated R&D spending around ¥116 billion in FY2023, funding lab work and process scale-up. Clinical studies and regulatory evidence incur material trial and CRO costs, especially in biopharma divisions. AI development adds rising GPU and cloud compute expenses. Active portfolio management shifts capital toward higher-return projects to mitigate clinical and technological risk.
Manufacturing and COGS
Raw materials, specialty components and utilities are the primary cost drivers in Fujifilm’s manufacturing lines; in FY2024 consolidated net sales were 2,803.9 billion yen, with cost of goods sold around 58% of sales. GMP compliance in the pharmaceutical/biotech segment raises overhead through validation, cleanrooms and QA staffing. Yield losses and scrap materially compress margins in film and chemical processes. Automation investments in 2024 improved throughput and helped offset labor intensity.
Sales, marketing, and distribution
Field sales, channel margins and promotions drive significant SG&A spend for Fujifilm; in FY2024 consolidated revenue was about 3.20 trillion yen, with sales, marketing and distribution absorbing a sizable share for channel incentives and demo units/events that raise unit costs. Ongoing digital marketing, portal maintenance and training programs add recurring expenses to support adoption and partner effectiveness.
Service, warranty, and field operations
Fujifilm’s service cost base is driven by spare parts inventory, global logistics and technician labor, with its service network operating in over 100 countries and consolidated revenue near 2.5 trillion yen in FY2023–24, making fixed global coverage material to overheads.
Remote monitoring infrastructure and warranty reserves are used to hedge failure risk and reduce on-site visits, while warranty provisioning and spare-parts stocking remain key fixed-cost drivers.
- spare-parts, logistics, labor
- remote monitoring platform
- warranty reserves hedge failures
- global coverage → higher fixed costs
Regulatory, quality, and corporate overhead
Regulatory, quality, and corporate overhead at Fujifilm cover global compliance and periodic audits across its >80,000 workforce, strict documentation for life‑science and imaging products, centralized IT, cybersecurity and data‑governance controls, ongoing facilities and administration costs for manufacturing and labs, plus IP protection for a portfolio of over 40,000 patents and corporate insurance programs.
- employees: >80,000
- patents: >40,000
- global audits & compliance: continuous
- IT/cyber & data governance: centralized
R&D-heavy imaging and healthcare conglomerate with rising AI/cloud costs
Fujifilm’s cost base centers on R&D (¥116b FY2023), COGS (~58% of sales), GMP/regulatory overheads and global service/spare‑parts networks; FY2024 revenue ~¥3.20t with heavy fixed costs from >80,000 employees and 40,000+ patents. AI/cloud and clinical trials are rising variable costs; portfolio reallocation limits capital exposure.
| Metric | Value |
|---|---|
| Revenue FY2024 | ¥3.20t |
| Net sales (FY2024) | ¥2,803.9b |
| R&D (FY2023) | ¥116b |
| COGS | ~58% |
| Employees | >80,000 |
| Patents | >40,000 |
Revenue Streams
Medical systems and informatics sales
Revenue from imaging equipment, PACS and software licenses forms Fujifilm’s core medical-systems income, tapping a global medical imaging market valued at about $43.1 billion in 2024. Bundled installations and services boost average deal sizes, while upgrades and paid options lift gross margins. Multi-site rollouts drive operating leverage and recurring license renewals, scaling revenue per customer.
CDMO and biopharma services
Fujifilm's CDMO and biopharma services generate fees across process development, clinical and commercial manufacturing, with milestone and tech‑transfer charges tied to program progression. Capacity reservation and slot fees secure plant time across Diosynth and cell‑therapy sites in 2024. Long‑term contracts and multi‑year supply agreements stabilize cash flows and backlog visibility.
Materials, optics, and industrial products
Sales of films, photoresists, optical components and coatings form a core revenue stream, with custom formulations commanding price premiums and higher margins. Framework supply agreements with OEMs secure multi-year demand and volume visibility. Recurring orders follow customers production cycles, smoothing revenue recognition. Materials-driven products helped Fujifilm support group revenue of about ¥2.7 trillion in FY2023 (ended March 2024).
Consumables and supplies
Software, subscriptions, and services
Software, subscriptions, and services drive recurring revenue through SaaS for workflow, visualization, and asset management, complemented by maintenance, training, and extended warranties; Fujifilm reported consolidated results for the year ended March 31, 2024, emphasizing services-led growth. Remote monitoring and analytics subscriptions plus professional integration services expand lifetime customer value and margins.
- SaaS workflow/visualization/asset mgmt
- Maintenance, training, warranties
- Remote monitoring & analytics subs
- Professional integration services
Imaging, CDMO and consumables drive recurring revenue across a $43.1B market
Revenue centers: medical imaging equipment, PACS/software and services capture a global medical imaging market ~ $43.1B in 2024, with bundled installations and recurring license renewals; CDMO/biopharma services deliver milestone and capacity fees via long‑term contracts; materials, consumables and SaaS/subscriptions convert installed base into annuities, supporting Fujifilm’s scale.
| Metric | Value |
|---|---|
| Global medical imaging market (2024) | $43.1B |
| Fujifilm consolidated revenue (FY2023) | ¥2.70 trillion |